



**Smart
investments,
health
returns.**

www.capitalcell.com

ABOUT US

What We Do

We are the world's **leading alternative investment platform for early-stage biotech and life science companies**—two of the most profitable and impactful sectors in the world.

We bring together innovative biotech companies and investors, to **bridge the funding gap**.



Daniel Oliver

Director of Capital Cell



Regulation

We are a **licensed provider** in compliance with European regulations, and we operate **under supervision of the EU financial authorities**.



*We are a platform authorized and supervised by the Comisión Nacional del Mercado de Valores with PFP license nº17 and ECSP (European Crowdfunding Service Provider) license.

WHY US

Selection Process



BioExpert Network

A proprietary network of over 3,000 vetted experts who analyze the project's potential based on the Team, Science, Innovation, and Business Potential.

Only **5%** of companies that apply to Capital Cell pass all filters

Due Diligence

Capital Cell uses internal resources and strategic partnerships to provide investors with transparent results:

- Financial
- Legal
- Market Access
- Intellectual Property
- Regulatory

Lead Investor

Only opportunities with a suitable, credible and knowledgeable Lead Investor are approved for investment.

Historically, lead investors have been:

- 40% Venture Capital
- 42% Business Angels & Family Offices
- 18% Corporate / Incubators

**Selected by experts,
backed by visionaries.**

WHY US

Selection Process



BioExpert Network

A proprietary network of over 3,000 vetted experts who analyze the project's potential based on the Team, Science, Innovation, and Business Potential.

Our Selection Process Partners:



Science



Financial



Patents and IP



Regulatory and Market Access

“

Overall excellent, from the scientific basis to the potential of the lead compound, the medical device and the management team, backed by the early clinical success already achieved and the recent IND filing - full support for this proposed investment.

”



Marc Brehme
Founder and managing director

“

Capital Cell enabled us to bring together a broad and diverse base of investors quickly and efficiently through an online campaign that exceeded all expectations more than doubling our target in just a few weeks. We reached geographies where we traditionally had little visibility, and were supported throughout by a truly professional team.

”



Mathieu Horras
CEO of Aspivix



SUCCESS STORIES

from France



656 investors
2.198.920€ investment achieved
146.6% invested

Axoltis Pharma is developing NX210c, which restores the blood-brain barrier (BBB), a key factor in ALS, Alzheimer's, Parkinson's, and other neurodegenerative diseases.



105 investors
571.247€ investment achieved
142.8% invested

AbTx designs personalized medicine biotherapies . These "next-generation drugs" are antibody-drug conjugates (ADCs) that target cancer cells while simultaneously delivering chemotherapy, thus reducing its side effects.

***Active campaign**



272 investors
1.322.920€ investment achieved
110.2% invested

Hemerion's first "best-in-class" drug-device therapeutic is dedicated to Brain Cancer, with a promising strategy to significantly improve the outcomes in Glioblastoma, the most common and aggressive brain cancer.

***Now raising a Series B**

SUCCESS STORIES

from Switzerland



309 investors
2.896.753€ investment achieved
126% invested

OxyPrem's mission is newborn brain protection for prematurely-born children, in the days and weeks after birth. Its sensors enable clinicians to react before brain injury happens, to avoid life-long consequences.



103 investors
700.000€ target
96.2% invested

EVis NanoVector is an innovative platform for loading RNA into extracellular vesicles, enabling safe, precise, and scalable personalized medicine.

***Active campaign**



360 investors
2.682.113€ investment achieved
124.8% invested

Aspivix revolutionizes women's healthcare with Carevix™, a non-invasive method that replaces cervical tenaculum, making intrauterine device (IUD) procedures gentler and more accessible.

SUCCESS STORIES

from Spain



399 investors
1.266.062€ investment achieved
105.5% invested

ELEM is offering in silico clinical trial services on virtual populations of human avatars using supercomputers. With these in silico trials, we help our clients in the pharmaceutical and medical device industries optimize and personalize therapies for heart disease.



303 investors
1.883.282€ target
125.6% invested

Nanobots Therapeutics develops innovative therapies using nanorobots capable of self-propelling in body fluids and crossing complex biological barriers. These nanovehicles enable the delivery of treatments directly to target tissue, including solid tumours.



165 investors
721.568€ investment achieved
131.2% invested

SERVATRIX Biomed is dedicated to developing advanced treatments for fatty liver disease, particularly non-alcoholic steatohepatitis (NASH), and its progression to liver fibrosis and cirrhosis.

HOW IT WORKS

Investment Portfolio Diversification




An early-stage Health & Biotech investment portfolio is most often uncorrelated with investment in stocks, bonds and real estate, as **it is innovation-driven** and tied to approvals and progressing through clinical trials.


[Explore Investment Opportunities](#)



SECTORS



DEAL SIZE



Capital Cell brings the experience of **153 investment rounds for 129 companies** in a diversified and increasingly valuable portfolio.

AND IT WORKS

Track-Record (2015 - 2025)



153

Investment Rounds

23.500

Registered investors

50 %

Typical tax discount

146 M€

Total Investment

93,8%

Survival Rate

5

Exits

2,70 x

Portfolio value 2015-2022

5,42 x

Portfolio value 2015-2018

23,5 %


Equivalent return rate 2015-2018

EXITS & PERFORMANCE

How you will make money



- **Licensing** - Acquisition of the product by a Pharma company
- **Initial Public Offering (IPO)**
- **M&A** - This can generate a dividend and provide an opportunity to sell the shares.

	 MOIC	 IRR	 DEAL
	91,2x	112,16%	Acquired by Arcutis BioTherapeutics for €400M.
	1,75x	32,29%	Acquired by Hipra for its diagnostic and therapeutic tech for digestive diseases.
	3,12x	25,55%	Successful IPO with its state-of-art production of plant cell cultures.

WE GOT YOU

Invest with a hassle-free experience



* Think after you buy

- You will have 7 days to cancel any investment, no questions asked
- Commit your investment today, pay in a few weeks (or cancel!)


* All the information

- Quarterly reports of all your investments
- Speak to a dedicated Investment Relations agent at any time.

* Here for you

- **Ask before you buy!** Don't hesitate in talking to us.

[REGISTER HERE](#)



THANK YOU

Contact us:



info@capitalcell.net

